Herceptin Injection 150 Milligrams (Trastuzumab) (Monoclonal Antibody, Recombinant DNA)

Adult administration

Used for the treatment of metastatic breast cancer and early breast cancer, as well as metastatic gastric cancer. 1-week regimen - Initial loading dose: 4 mg/kg administered - Maintenance dose: 2 mg/kg administered weekly 3-week regimen - Initial loading dose: 8 mg/kg administered - Maintenance dose: 6 mg/kg administered every 3 weeks Administration should be performed as an intravenous infusion over 90 minutes, and rapid intravenous administration is prohibited. For breast cancer treatment, administer in conjunction with docetaxel, paclitaxel, or aromatase inhibitors.

This medication may affect heart function; therefore, patients with heart disease or a history of heart problems must have their cardiac status carefully evaluated prior to administration. Care should be taken when administering this drug to patients with symptoms of heart failure or low ejection fraction. The drug may cause allergic reactions or infusion-related side effects during administration, hence the patient's condition should be closely monitored during the infusion. If symptoms such as difficulty breathing, hypotension, or rash occur, administration must be halted immediately and appropriate treatment should be given. Patients with lung issues or a history of pulmonary disease should also exercise caution when receiving this drug. Women who are pregnant or may become pregnant should avoid pregnancy during treatment and for some time thereafter, and breastfeeding should be discontinued if currently nursing. The safety and efficacy of this drug in children have not been established, and its use is not recommended in this population. Elderly patients or those with impaired kidney and liver function can use the drug without special dose adjustments, but close monitoring is necessary based on their condition. The injection solution should be prepared under aseptic conditions and used as soon as possible after reconstitution. This drug should not be mixed with other medications, and only the specified diluent should be used. Dizziness or drowsiness may occur during administration; therefore, driving or operating machinery should be avoided until symptoms resolve.

Serious side effects

Hives, severe swelling (including angioedema, facial swelling), chest tightness, difficulty breathing, anaphylaxis, hypotension, wheezing, bronchospasm, ventricular tachycardia, decreased oxygen saturation, anaphylactic shock, respiratory distress syndrome, pulmonary infiltrates including interstitial lung disease, acute respiratory distress syndrome, pneumonia, interstitial pneumonitis, pleural effusion, acute pulmonary edema, respiratory failure, cardiac dysfunction (congestive heart failure, decreased left ventricular ejection fraction, myocardial toxicity.

Mild side effects

• Nausea
• myalgia
• neutropenia
• neuropathy
• fever
• chills
• anorexia
• peripheral neuropathy
• vomiting
• weakness

This medication should be stored in a sealed container to prevent exposure to air and should be kept refrigerated at a temperature between 2 degrees and 8 degrees Celsius. Storing the drug in this manner maintains its efficacy and prevents degradation.

Appearance

A colorless, transparent vial containing a white to slightly yellow freeze-dried powder.

Package unit

1 vial/box